Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
| ChEMBL ligand: CHEMBL559147 |
|---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
| DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
|---|---|---|---|---|---|---|---|---|
| C-C motif chemokine 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1649052] [UniProtKB: P13500] | ||||||||
| ChEMBL | Inhibition of MCP1-mediated human THP cell migration | B | 5.58 | pIC50 | 2630.27 | nM | IC50 | Bioorg Med Chem Lett (2011) 21: 97-101 [PMID:21145740] |
| Huntingtin in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5514] [UniProtKB: P42858] | ||||||||
| ChEMBL | Inhibition of HTT (unknown origin) | B | 5.3 | pIC50 | 5000 | nM | IC50 | J Med Chem (2022) 65: 15993-16032 [PMID:36490325] |
| leucine rich repeat kinase 2/Leucine-rich repeat serine/threonine-protein kinase 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1075104] [GtoPdb: 2059] [UniProtKB: Q5S007] | ||||||||
| ChEMBL | Inhibition of GST-tagged LRRK2 G2019S/A2016T mutant (1326 to 2527 residues) (unknown origin) in presence of ATP | B | 4.89 | pIC50 | 13000 | nM | IC50 | Biochem J (2009) 424: 47-60 [PMID:19740074] |
| ChEMBL | Inhibition of GST-tagged LRRK2 (1326 to 2527 residues) (unknown origin) using peptide as substrate incubated for 15 mins in presence of ATP by immunoblotting analysis | B | 5.64 | pIC50 | 2300 | nM | IC50 | Biochem J (2009) 424: 47-60 [PMID:19740074] |
| ChEMBL | Inhibition of GST-tagged LRRK2 G2019S mutant (1326 to 2527 residues) (unknown origin) using peptide as substrate incubated for 15 mins in presence of ATP by immunoblotting analysis | B | 6 | pIC50 | 1000 | nM | IC50 | Biochem J (2009) 424: 47-60 [PMID:19740074] |
| ChEMBL | Inhibition of GST-tagged LRRK2 G2019S mutant (1326 to 2527 residues) (unknown origin) in presence of ATP | B | 6 | pIC50 | 1000 | nM | IC50 | Biochem J (2009) 424: 47-60 [PMID:19740074] |
| Rho associated coiled-coil containing protein kinase 1/Rho-associated protein kinase 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3231] [GtoPdb: 1503] [UniProtKB: Q13464] | ||||||||
| ChEMBL | Inhibition of ROCK1 (unknown origin) | B | 6.66 | pKi | 220 | nM | Ki | Medchemcomm (2012) 3: 699-709 [PMID:23275831] |
| ChEMBL | Inhibition of ROCK1 (unknown origin) | B | 6.66 | pKi | 220 | nM | Ki | Eur J Med Chem (2023) 250: 115181-115181 [PMID:36764122] |
| ChEMBL | Inhibition of human leukocytic ROCK1 expressed in insect cells using KKRNRTLSV as substrate after 10 mins by pyruvate kinase/lactate dehydrogenase coupled assay | B | 6.82 | pKi | 150 | nM | Ki | J Med Chem (2015) 58: 5028-5037 [PMID:26039570] |
| ChEMBL | Inhibitory constant against ROCK1 | B | 6.82 | pKi | 150 | nM | Ki | J Biol Chem (2006) 281: 260-268 [PMID:16249185] |
| ChEMBL | Inhibition of human ROCK1 by homogenous luciferase assay | B | 6.82 | pKi | 150 | nM | Ki | J Med Chem (2010) 53: 759-777 [PMID:20000469] |
| GtoPdb | - | - | 6.85 | pKi | 140 | nM | Ki | Nature (1997) 389: 990-4 [PMID:9353125] |
| ChEMBL | Inhibition of ROCK1 (unknown origin) | B | 6.85 | pKi | 140 | nM | Ki | J Med Chem (2021) 64: 1283-1345 [PMID:33481605] |
| ChEMBL | ROCK1 and ROCK2 Compound Selectivity: Dose response curves for Rho-kinase inhibition were derived from a Millipore immuno-based 96 well plate assay (Millipore catalog number CSA001). Purified active ROCK1 and ROCK2 were obtained from Invitrogen (catalog numbers ROCK1, PV3691 and ROCK2, PV3759). The kit components include assay plates, which are pre-coated with recombinant MYPT1, which contains a specifically phosphorylatable Thr696. The inhibitory activities of compounds are measured according to the manufactures protocol. Briefly, decreasing concentrations of test compounds or the known ROCK inhibitor Y-27963, are added, from 50 uM to 0.003 uM to reaction buffer containing 5 mM MgCl2, and 10 mUnits of ROCK1 or ROCK2 in assay dilution buffer. This mixture is overlayed into the 96 well plate and the reaction is initiated with the addition of 2.5 uM ATP. The assay proceeds at 30° Celsius for 30 minutes with gentle shaking at 120 rpm. The assay is terminated by washing of the plate 3 times with Tris-buffered saline and tween wash buffer. Anti-phospho-MYPT1 (Thr696) antibody is added to each well to detect the phosphorylated substrate and incubated for 1 hour at room temperature after which HRP conjugated anti-rabbit IgG secondary is added for 1 hour at room temperature. After washing the assay is developed using a substrate reagent and the absorbance is read at 450 nm on a Tecan Infinite M1000 reflecting the relative remaining ROCK phosphorylation activity. | B | 7.4 | pKi | 40 | nM | Ki | US-10183931-B2. Rho kinase inhibitors (2019) |
| ChEMBL | Inhibition of ROCK-1 | B | 7.6 | pKi | 25.12 | nM | Ki | Bioorg Med Chem Lett (2011) 21: 97-101 [PMID:21145740] |
| ChEMBL | Inhibition of N terminal histidine tagged human recombinant ROCK1 (3 to 543 residues) in HASMC cells incubated for 2 hrs by ELISA method | B | 4.52 | pIC50 | 30000 | nM | IC50 | J Med Chem (2021) 64: 1786-1815 [PMID:33569941] |
| ChEMBL | Inhibition of N terminal histidine tagged human recombinant ROCK1 (3 to 543 residues) expressed in baculovirus infected Sf9 cells using biotin-Ahx-AKRRRLSSLRA-CONH2 as a substrate incubated for 10 mins by scintillation counting method | B | 5.85 | pIC50 | 1400 | nM | IC50 | J Med Chem (2021) 64: 1786-1815 [PMID:33569941] |
| ChEMBL | ROCK1 and ROCK2 Compound Selectivity: Dose response curves for Rho-kinase inhibition were derived from a Millipore immuno-based 96 well plate assay (Millipore catalog number CSA001). Purified active ROCK1 and ROCK2 were obtained from Invitrogen (catalog numbers ROCK1, PV3691 and ROCK2, PV3759). The kit components include assay plates, which are pre-coated with recombinant MYPT1, which contains a specifically phosphorylatable Thr696. The inhibitory activities of compounds are measured according to the manufactures protocol. Briefly, decreasing concentrations of test compounds or the known ROCK inhibitor Y-27963, are added, from 50 uM to 0.003 uM to reaction buffer containing 5 mM MgCl2, and 10 mUnits of ROCK1 or ROCK2 in assay dilution buffer. This mixture is overlayed into the 96 well plate and the reaction is initiated with the addition of 2.5 uM ATP. The assay proceeds at 30° Celsius for 30 minutes with gentle shaking at 120 rpm. The assay is terminated by washing of the plate 3 times with Tris-buffered saline and tween wash buffer. Anti-phospho-MYPT1 (Thr696) antibody is added to each well to detect the phosphorylated substrate and incubated for 1 hour at room temperature after which HRP conjugated anti-rabbit IgG secondary is added for 1 hour at room temperature. After washing the assay is developed using a substrate reagent and the absorbance is read at 450 nm on a Tecan Infinite M1000 reflecting the relative remaining ROCK phosphorylation activity. | B | 5.95 | pIC50 | 1130 | nM | IC50 | US-10183931-B2. Rho kinase inhibitors (2019) |
| ChEMBL | Inhibition of ROCK-1 by Immobilized metal ion affinity-based fluorescence polarization assay | B | 6.06 | pIC50 | 870.96 | nM | IC50 | Bioorg Med Chem Lett (2011) 21: 97-101 [PMID:21145740] |
| ChEMBL | Inhibition of ROCK1 (unknown origin) | B | 6.7 | pIC50 | 200 | nM | IC50 | J Med Chem (2016) 59: 788-809 [PMID:26356532] |
| ChEMBL | Inhibition of human recombinant N-terminal his-tagged ROCK1 (3-543) expressed in baculovirus infected Sf9 cells using Biotin-Ahx-AKRRLSSLRA-CONH2 substrate and [gamma-33P]ATP after 90 mins by scintillation proximity assay | B | 6.82 | pIC50 | 150 | nM | IC50 | J Pharmacol Exp Ther (2007) 320: 89-98 [PMID:17018693] |
| ChEMBL | Inhibition of ROCK-1 (unknown origin) | B | 7.03 | pIC50 | 93 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 4812-4817 [PMID:25248678] |
| GtoPdb | - | - | 7.34 | pIC50 | 46 | nM | IC50 |
Bioorg Med Chem Lett (2010) 20: 3235-9 [PMID:20462760]; Hypertension (2009) 54: 676-83 [PMID:19597037] |
| Rho associated coiled-coil containing protein kinase 2/Rho-associated protein kinase 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2973] [GtoPdb: 1504] [UniProtKB: O75116] | ||||||||
| ChEMBL | Inhibition of human ROCK2 by homogenous luciferase assay | B | 6.52 | pKi | 300 | nM | Ki | J Med Chem (2010) 53: 759-777 [PMID:20000469] |
| ChEMBL | Inhibition of ROCK2 (unknown origin) | B | 6.52 | pKi | 300 | nM | Ki | Medchemcomm (2012) 3: 699-709 [PMID:23275831] |
| ChEMBL | Inhibition of ROCK2 (unknown origin) | B | 6.52 | pKi | 300 | nM | Ki | J Med Chem (2021) 64: 1283-1345 [PMID:33481605] |
| ChEMBL | Inhibition of human ROCK2 (unknown origin) | B | 6.52 | pKi | 300 | nM | Ki | Eur J Med Chem (2023) 250: 115181-115181 [PMID:36764122] |
| ChEMBL | Inhibition of ROCK2 (unknown origin) assessed as inhibition constant | B | 6.85 | pKi | 140 | nM | Ki | J Med Chem (2016) 59: 2269-2300 [PMID:26486225] |
| GtoPdb | - | - | 6.94 | pKi | 114 | nM | Ki |
Nature (1997) 389: 990-4 [PMID:9353125]; Hypertension (2009) 54: 676-83 [PMID:19597037] |
| ChEMBL | ROCK1 and ROCK2 Compound Selectivity: Dose response curves for Rho-kinase inhibition were derived from a Millipore immuno-based 96 well plate assay (Millipore catalog number CSA001). Purified active ROCK1 and ROCK2 were obtained from Invitrogen (catalog numbers ROCK1, PV3691 and ROCK2, PV3759). The kit components include assay plates, which are pre-coated with recombinant MYPT1, which contains a specifically phosphorylatable Thr696. The inhibitory activities of compounds are measured according to the manufactures protocol. Briefly, decreasing concentrations of test compounds or the known ROCK inhibitor Y-27963, are added, from 50 uM to 0.003 uM to reaction buffer containing 5 mM MgCl2, and 10 mUnits of ROCK1 or ROCK2 in assay dilution buffer. This mixture is overlayed into the 96 well plate and the reaction is initiated with the addition of 2.5 uM ATP. The assay proceeds at 30° Celsius for 30 minutes with gentle shaking at 120 rpm. The assay is terminated by washing of the plate 3 times with Tris-buffered saline and tween wash buffer. Anti-phospho-MYPT1 (Thr696) antibody is added to each well to detect the phosphorylated substrate and incubated for 1 hour at room temperature after which HRP conjugated anti-rabbit IgG secondary is added for 1 hour at room temperature. After washing the assay is developed using a substrate reagent and the absorbance is read at 450 nm on a Tecan Infinite M1000 reflecting the relative remaining ROCK phosphorylation activity. | B | 7.22 | pKi | 60 | nM | Ki | US-10183931-B2. Rho kinase inhibitors (2019) |
| ChEMBL | ROCK1 and ROCK2 Compound Selectivity: Dose response curves for Rho-kinase inhibition were derived from a Millipore immuno-based 96 well plate assay (Millipore catalog number CSA001). Purified active ROCK1 and ROCK2 were obtained from Invitrogen (catalog numbers ROCK1, PV3691 and ROCK2, PV3759). The kit components include assay plates, which are pre-coated with recombinant MYPT1, which contains a specifically phosphorylatable Thr696. The inhibitory activities of compounds are measured according to the manufactures protocol. Briefly, decreasing concentrations of test compounds or the known ROCK inhibitor Y-27963, are added, from 50 uM to 0.003 uM to reaction buffer containing 5 mM MgCl2, and 10 mUnits of ROCK1 or ROCK2 in assay dilution buffer. This mixture is overlayed into the 96 well plate and the reaction is initiated with the addition of 2.5 uM ATP. The assay proceeds at 30° Celsius for 30 minutes with gentle shaking at 120 rpm. The assay is terminated by washing of the plate 3 times with Tris-buffered saline and tween wash buffer. Anti-phospho-MYPT1 (Thr696) antibody is added to each well to detect the phosphorylated substrate and incubated for 1 hour at room temperature after which HRP conjugated anti-rabbit IgG secondary is added for 1 hour at room temperature. After washing the assay is developed using a substrate reagent and the absorbance is read at 450 nm on a Tecan Infinite M1000 reflecting the relative remaining ROCK phosphorylation activity. | B | 5.79 | pIC50 | 1630 | nM | IC50 | US-10183931-B2. Rho kinase inhibitors (2019) |
| ChEMBL | Inhibition of Protein kinase ROCK2 (ROCKII) | B | 6.15 | pIC50 | 700 | nM | IC50 | J Med Chem (2003) 46: 1478-1483 [PMID:12672248] |
| ChEMBL | Inhibition of His6-tagged ROCK2 (2 to 543 residues) (unknown origin) using peptide as substrate incubated for 15 mins in presence of ATP by immunoblotting analysis | B | 6.15 | pIC50 | 700 | nM | IC50 | Biochem J (2009) 424: 47-60 [PMID:19740074] |
| ChEMBL | Inhibition of human ROCK2 by homogenous luciferase assay | B | 6.59 | pIC50 | 260 | nM | IC50 | J Med Chem (2010) 53: 759-777 [PMID:20000469] |
| ChEMBL | Inhibition of ROCK-2 by Immobilized metal ion affinity-based fluorescence polarization assay | B | 6.61 | pIC50 | 245.47 | nM | IC50 | Bioorg Med Chem Lett (2011) 21: 97-101 [PMID:21145740] |
| ChEMBL | Inhibition of recombinant N-terminal GST-tagged human ROCK2 (5 to 554 residues) expressed in baculovirus infected Sf9 cells using S6K as substrate incubated for 30 mins in presence of ATP by ADP Glo kinase assay | B | 6.84 | pIC50 | 143 | nM | IC50 | J Med Chem (2022) 65: 9819-9845 [PMID:35816678] |
| ChEMBL | Inhibition of ROCK2 (unknown origin) | B | 6.85 | pIC50 | 140 | nM | IC50 | J Med Chem (2016) 59: 788-809 [PMID:26356532] |
| ChEMBL | Inhibition of human recombinant ROCK-2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate after 40 mins by scintillation counting analysis | B | 7.05 | pIC50 | 89 | nM | IC50 | Bioorg Med Chem Lett (2014) 24: 4812-4817 [PMID:25248678] |
| GtoPdb | - | - | 7.21 | pIC50 | 61 | nM | IC50 |
Bioorg Med Chem Lett (2010) 20: 3235-9 [PMID:20462760]; Hypertension (2009) 54: 676-83 [PMID:19597037] |
| ChEMBL | Inhibition of ROCK2 (unknown origin) using long S6 kinase peptide as substrate by radiometric assay | B | 7.27 | pIC50 | 54 | nM | IC50 | Bioorg Med Chem Lett (2013) 23: 6442-6446 [PMID:24119557] |
| ChEMBL | Inhibition of human N-terminal GST-tagged ROCK2 expressed in baculovirus-infected insect cells using long S6 kinase peptide as substrate by radiometric assay in presence of [32P]ATP | B | 7.27 | pIC50 | 54 | nM | IC50 | J Med Chem (2015) 58: 4309-4324 [PMID:25898023] |
| ChEMBL | Inhibition of ROCK2 (unknown origin) assessed as phosphorylation of MYPT1 using Tetramethylbenzidine as substrate in presence of ATP | B | 8.08 | pIC50 | 8.3 | nM | IC50 | ACS Med Chem Lett (2020) 11: 1694-1703 [PMID:32944136] |
| Rho associated coiled-coil containing protein kinase 2/Rho-associated protein kinase 2 in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5490] [GtoPdb: 1504] [UniProtKB: Q62868] | ||||||||
| ChEMBL | Inhibition of rat ROCK2 expressed in Sf9 cells | B | 6.1 | pIC50 | 800 | nM | IC50 | Biochem J (2000) 351: 95-105 [PMID:10998351] |
| ribosomal protein S6 kinase A5/Ribosomal protein S6 kinase alpha-5 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4237] [GtoPdb: 1523] [UniProtKB: O75582] | ||||||||
| ChEMBL | Inhibition of His-tagged human MSK1 expressed in Sf9 cells | B | 5.08 | pIC50 | 8300 | nM | IC50 | Biochem J (2000) 351: 95-105 [PMID:10998351] |
| protein kinase N2/Serine/threonine-protein kinase N2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3032] [GtoPdb: 1521] [UniProtKB: Q16513] | ||||||||
| ChEMBL | Inhibition of Protein kinase C related kinase 2 (PRK2) | B | 6.22 | pIC50 | 600 | nM | IC50 | J Med Chem (2003) 46: 1478-1483 [PMID:12672248] |
| ChEMBL | Inhibition of His-tagged human PRK2 expressed in HEK293 cells | B | 6.22 | pIC50 | 600 | nM | IC50 | Biochem J (2000) 351: 95-105 [PMID:10998351] |
| GtoPdb | - | - | 7.15 | pIC50 | 70 | nM | IC50 | Bioorg Med Chem Lett (2010) 20: 3235-9 [PMID:20462760] |
| Kv11.1/Voltage-gated inwardly rectifying potassium channel KCNH2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL240] [GtoPdb: 572] [UniProtKB: Q12809] | ||||||||
| ChEMBL | Displacement of [3H]dofetilide from human ERG | B | 4.1 | pKi | 79432.82 | nM | Ki | Bioorg Med Chem Lett (2011) 21: 97-101 [PMID:21145740] |
| protein kinase C epsilon in Human [GtoPdb: 1486] [UniProtKB: Q02156] | ||||||||
| GtoPdb | - | - | 6.47 | pIC50 | 335 | nM | IC50 | Bioorg Med Chem Lett (2010) 20: 3235-9 [PMID:20462760] |
ChEMBL data shown on this page come from version 36:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]